Vlado Perkovic's Publications

The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial
Journal articles
2020
Journal of the American Society of Nephrology
The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial
Journal articles
2020
Journal of the American Society of Nephrology
Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial
Journal articles
2020
Journal of the American Society of Nephrology
Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial
Journal articles
2020
Journal of the American Society of Nephrology
Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program
Journal articles
2020
Journal of the American Society of Nephrology
Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE
Journal articles
2020
Journal of the American Society of Nephrology
Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis
Journal articles
2020
Journal of the American Society of Nephrology
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial
Journal articles
2020
Journal of the American Society of Nephrology
SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS
Journal articles
2020
Kidney International Reports
SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA A SYSTEMATIC REVIEW AND ANALYSIS
Journal articles
2020
Kidney International Reports
THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL
Journal articles
2020
Journal of the American College of Cardiology
SUN-161 CIRCULATING AUTOANTIBODIES TOERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES
Journal articles
2020
Kidney International Reports
Varying association of extended hours dialysis with quality of life
Journal articles
2019
Clinical Journal of the American Society of Nephrology
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
Journal articles
2019
The Lancet Rheumatology
Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial
Conference Papers
2019
DIABETES-METABOLISM RESEARCH AND REVIEWS
Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c 7%: Results From the CREDENCE Trial
Conference Papers
2019
CIRCULATION
Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review
Journal articles
2019
BMJ Global Health
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Journal articles
2019
The Lancet Diabetes and Endocrinology
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
Journal articles
2019
Diabetologia
Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering
Journal articles
2019
CMAJ
P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease
Journal articles
2019
European Heart Journal
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Journal articles
2019
Diabetologia
Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis
Journal articles
2019
JAMA Internal Medicine
Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial
Journal articles
2019
Nephrology
Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER
Conference Abstracts
2019
DIABETOLOGIA
An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes
Conference Abstracts
2019
DIABETOLOGIA

Previous Next

Vlado Perkovic's Publications

The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial

The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial

Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program

Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE

Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis

Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial

SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS

SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA A SYSTEMATIC REVIEW AND ANALYSIS

THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

SUN-161 CIRCULATING AUTOANTIBODIES TOERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES

Varying association of extended hours dialysis with quality of life

The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial

Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c 7%: Results From the CREDENCE Trial

Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis

Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country